|
1
|
Louten J, Rankin AL, Li Y, Murphy EE,
Beaumont M, Moon C, Bourne P, McClanahan TK, Pflanz S and de Waal
Malefyt R: Endogenous IL-33 enhances Th2 cytokine production and
T-cell responses during allergic airway inflammation. Int Immunol.
23:307–315. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Onda H, Kasuya H, Takakura K, et al:
Identification of genes differentially expressed in canine
vasospastic cerebral arteries after subarachnoid hemorrhage. J
Cereb Blood Flow Metab. 19:1279–1288. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Baekkevold ES, Roussigné M, Yamanaka T,
Johansen FE, Jahnsen FL, Amalric F, Brandtzaeg P, Erard M,
Haraldsen G and Girard JP: Molecular characterization of NF-HEV, a
nuclear factor preferentially expressed in human high endothelial
venules. Am J Pathol. 163:69–79. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schmitz J, Owyang A, Oldham E, Song Y,
Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X,
Gorman DM, et al: IL-33, an interleukin-1-like cytokine that
signals via the IL-1 receptor-related protein ST2 and induces T
helper type 2-associated cytokines. Immunity. 23:479–490. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Marian AJ: Pathogenesis of diverse
clinical and pathological phenotypes in hypertrophic
cardiomyopathy. Lancet. 355:58–60. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bartemes KR, Iijima K, Kobayashi T,
Kephart GM, McKenzie AN and Kita H: IL-33-responsive lineage- CD25+
CD44(hi) lymphoid cells mediate innate type 2 immunity and allergic
inflammation in the lungs. J Immunol. 188:1503–1513. 2012.
View Article : Google Scholar :
|
|
7
|
Miller AM and Liew FY: The IL-33/ST2
pathway–A new therapeutic target in cardiovascular disease.
Pharmacol Ther. 131:179–186. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Roussel L, Erard M, Cayrol C and Girard
JP: Molecular mimicry between IL-33 and KSHV for attachment to
chromatin through the H2A-H2B acidic pocket. EMBO Rep. 9:1006–1012.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Moussion C, Ortega N and Girard JP: The
IL-1-like cytokine IL-33 is constitutively expressed in the nucleus
of endothelial cells and epithelial cells in vivo: A novel
'alarmin'? PloS one. 3:e33312008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Carriere V, Roussel L, Ortega N, Lacorre
DA, Americh L, Aguilar L, Bouche G and Girard JP: IL-33, the
IL-1-like cytokine ligand for ST2 receptor, is a
chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci
USA. 104:282–287. 2007. View Article : Google Scholar :
|
|
11
|
Nakajima A: Application of cellular gene
therapy for rheumatoid arthritis. Mod Rheumatol. 16:269–275. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tsuda H, Komine M, Karakawa M, Etoh T,
Tominaga S and Ohtsuki M: Novel splice variants of IL-33:
Differential expression in normal and transformed cells. J Invest
Dermatol. 132:2661–2664. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cayrol C and Girard JP: The IL-1-like
cytokine IL-33 is inactivated after maturation by caspase-1. Proc
Natl Acad Sci USA. 106:9021–9026. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Creagh EM, Conroy H and Martin SJ:
Caspase-activation pathways in apoptosis and immunity. Immunol Rev.
193:10–21. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Luthi AU, Cullen SP, McNeela EA, Duriez
PJ, Afonina IS, Sheridan C, Brumatti G, Taylor RC, Kersse K,
Vandenabeele P, et al: Suppression of interleukin-33 bioactivity
through proteolysis by apoptotic caspases. Immunity. 31:84–98.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhao W and Hu Z: The enigmatic processing
and secretion of interleukin-33. Cell Mol Immunol. 7:260–262. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lamkanfi M and Dixit VM: IL-33 raises
alarm. Immunity. 31:5–7. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nakae S, Morita H, Ohno T, Arae K,
Matsumoto K and Saito H: Role of interleukin-33 in innate-type
immune cells in allergy. Allergol Int. 62:13–20. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tominaga S: A putative protein of a growth
specific cDNA from BALB/c-3T3 cells is highly similar to the
extracellular portion of mouse interleukin 1 receptor. FEBS Lett.
258:301–304. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Luzina IG, Pickering EM, Kopach P, Kang
PH, Lockatell V, Todd NW, Papadimitriou JC, McKenzie AN and Atamas
SP: Full-length IL-33 promotes inflammation but not Th2 response in
vivo in an ST2-independent fashion. J Immunol. 189:403–410. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Löhning M, Stroehmann A, Coyle AJ, Grogan
JL, Lin S, Gutierrez-Ramos JC, Levinson D, Radbruch A and Kamradt
T: T1/ST2 is preferentially expressed on murine Th2 cells,
independent of interleukin 4, interleukin 5 and interleukin 10 and
important for Th2 effector function. Proc Natl Acad Sci USA.
95:6930–6935. 1998. View Article : Google Scholar
|
|
22
|
Yanagisawa K, Naito Y, Kuroiwa K, Arai T,
Furukawa Y, Tomizuka H, Miura Y, Kasahara T, Tetsuka T and Tominaga
S: The expression of ST2 gene in helper T cells and the binding of
ST2 protein to myeloma-derived RPMI8226 cells. J Biochm.
121:95–103. 1997. View Article : Google Scholar
|
|
23
|
Shimizu M, Matsuda A, Yanagisawa K, Hirota
T, Akahoshi M, Inomata N, Ebe K, Tanaka K, Sugiura H, Nakashima K,
et al: Functional SNPs in the distal promoter of the ST2 gene are
associated with atopic dermatitis. Hum Mol Genet. 14:2919–2927.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lin J, Zhang L, Zhao G, Su Z, Deng R,
Pflugfelder SC and Li DQ: A novel interleukin 33/ST2 signaling
regulates inflammatory response in human corneal epithelium. PloS
One. 8:e609632013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Oboki K, Ohno T, Kajiwara N, Saito H and
Nakae S: IL-33 and IL-33 receptors in host defense and diseases.
Allergol Int. 59:143–160. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Smith DE: IL-33: A tissue derived cytokine
pathway involved in allergic inflammation and asthma. Clin Exp
Allergy. 40:200–208. 2010. View Article : Google Scholar
|
|
27
|
Oshikawa K, Kuroiwa K, Tago K, Iwahana H,
Yanagisawa K, Ohno S, Tominaga SI and Sugiyama Y: Elevated soluble
ST2 protein levels in sera of patients with asthma with an acute
exacerbation. Am J Respir Crit Care Med. 164:277–281. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Oshikawa K, Kuroiwa K, Tokunaga T, Kato T,
Hagihara SI, Tominaga SI and Sugiyama Y: Acute eosinophilic
pneumonia with increased soluble ST2 in serum and bronchoalveolar
lavage fluid. Respir Med. 95:532–533. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Weinberg EO, Shimpo M, De Keulenaer GW,
MacGillivray C, Tominaga S, Solomon SD, Rouleau JL and Lee RT:
Expression and regulation of ST2, an interleukin-1 receptor family
member, in cardiomyocytes and myocardial infarction. Circulation.
106:2961–2966. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tajima S, Oshikawa K, Tominaga S and
Sugiyama Y: The increase in serum soluble ST2 protein upon acute
exacerbation of idiopathic pulmonary fibrosis. Chest.
124:1206–1214. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Brunner M, Krenn C, Roth G, Moser B,
Dworschak M, Jensen-Jarolim E, Spittler A, Sautner T, Bonaros N,
Wolner E, et al: Increased levels of soluble ST2 protein and IgG1
production in patients with sepsis and trauma. Intensive Care Med.
30:1468–1473. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shimpo M, Morrow DA, Weinberg EO, Sabatine
MS, Murphy SA, Antman EM and Lee RT: Serum levels of the
interleukin-1 receptor family member ST2 predict mortality and
clinical outcome in acute myocardial infarction. Circulation.
109:2186–2190. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ohno T, Morita H, Arae K, Matsumoto K and
Nakae S: Interleukin-33 in allergy. Allergy. 67:1203–1214. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Brint EK, Xu D, Liu H, Dunne A, McKenzie
AN, O'Neill LA and Liew FY: ST2 is an inhibitor of interleukin 1
receptor and toll-like receptor 4 signaling and maintains endotoxin
tolerance. Nat Immunol. 5:373–379. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kakkar R and Lee RT: The IL-33/ST2
pathway: Therapeutic target and novel biomarker. Nat Rev Drug
Discov. 7:827–840. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kurowska-Stolarska M, Kewin P, Murphy G,
Russo RC, Stolarski B, Garcia CC, Komai-Koma M, Pitman N, Li Y,
Niedbala W, et al: IL-33 induces antigen-specific IL-5+ T cells and
promotes allergic-induced airway inflammation independent of IL-4.
J Immunol. 181:4780–4790. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chackerian AA, Oldham ER, Murphy EE,
Schmitz J, Pflanz S and Kastelein RA: IL-1 receptor accessory
protein and ST2 comprise the IL-33 receptor complex. J Immunol.
179:2551–2555. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kurowska-Stolarska M, Hueber A, Stolarski
B and McInnes IB: Interleukin-33: A novel mediator with a role in
distinct disease pathologies. J Internal Med. 269:29–35. 2011.
View Article : Google Scholar
|
|
39
|
Bulek K, Swaidani S, Qin J, Lu Y, Gulen
MF, Herjan T, Min B, Kastelein RA, Aronica M, Kosz-Vnenchak M and
Li X: The essential role of single Ig IL-1 receptor-related
molecule/Toll IL-1R8 in regulation of Th2 immune response. J
Immunol. 182:2601–2609. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Küchler AM, Pollheimer J, Balogh J,
Sponheim J, Manley L, Sorensen DR, De Angelis PM, Scott H and
Haraldsen G: Nuclear interleukin-33 is generally expressed in
resting endothelium but rapidly lost upon angiogenic or
proinflammatory activation. Am J Pathol. 173:1229–1242. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Smithgall MD, Comeau MR, Yoon BR, Kaufman
D, Armitage R and Smith DE: IL-33 amplifies both Th1- and Th2-type
responses through its activity on human basophils,
allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol.
20:1019–1030. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bianchi ME: DAMPs, PAMPs and alarmins: All
we need to know about danger. J Leukoc Biol. 81:1–5. 2007.
View Article : Google Scholar
|
|
43
|
Bao YS, Na SP, Zhang P, Jia XB, Liu RC, Yu
CY, Mu SH and Xie RJ: Characterization of interleukin-33 and
soluble ST2 in serum and their association with disease severity in
patients with chronic kidney disease. J Clin Immunol. 32:587–594.
2012. View Article : Google Scholar
|
|
44
|
Wiese CB, Toth CL, Tabet F, Taylor RC,
Landstreet SR, Rye KA, Hofmeister LH, Harrison DG, Kon V and
Vickers KC: HDL-microRNA-92a and interleukin-33 axis underlies
endothelial dysfunction associated with atherosclerosis and chronic
kidney disease. Arterioscler Thromb Vasc Biol. 34:A3. 2014.
|
|
45
|
Januzzi JL Jr, Peacock WF, Maisel AS, Chae
CU, Jesse RL, Baggish AL, O'Donoghue M, Sakhuja R, Chen AA, van
Kimmenade RR, et al: Measurement of the interleukin family member
ST2 in patients with acute dyspnea: Results from the PRIDE
(Pro-Brain natriuretic peptide investigation of dyspnea in the
emergency department) study. J Am Coll Cardiol. 50:607–613. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yu SL, Wong CK and Tam LS: The alarmin
functions of high-mobility group box-1 and IL-33 in the
pathogenesis of systemic lupus erythematosus. Expert Rev Clin
Immunol. 9:739–749. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wynn TA: Cellular and molecular mechanisms
of fibrosis. J Pathol. 214:199–210. 2008. View Article : Google Scholar
|
|
48
|
Rankin AL, Mumm JB, Murphy E, Turner S, Yu
N, McClanahan TK, Bourne PA, Pierce RH, Kastelein R and Pflanz S:
IL-33 induces IL-13-dependent cutaneous fibrosis. J Immunol.
184:1526–1535. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yang Z, Liang Y, Xi W, Li C and Zhong R:
Association of increased serum IL-33 levels with clinical and
laboratory characteristics of systemic lupus erythematosus in
Chinese population. Clin Exp Med. 11:75–80. 2011. View Article : Google Scholar
|
|
50
|
Caner S, Usluoğullari CA, Balkan F,
Büyükcam F, Kaya C, Saçıkara M, Koca C, Ersoy R and Çakır B: Is
IL-33 useful to detect early stage of renal failure? Ren Fail.
36:78–80. 2014. View Article : Google Scholar
|
|
51
|
Miller AM, Purves D, McConnachie A,
Asquith DL, Batty GD, Burns H, Cavanagh J, Ford I, McLean JS,
Packard CJ, et al: Soluble ST2 associates with diabetes but not
established cardiovascular risk factors: A new inflammatory pathway
of relevance to diabetes? PloS One. 7:e478302012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Basile DP, Anderson MD and Sutton TA:
Pathophysiology of acute kidney injury. Compr Physiol. 2:1303–1353.
2012.PubMed/NCBI
|
|
53
|
Galli SJ, Nakae S and Tsai M: Mast cells
in the development of adaptive immune responses. Nat Immunol.
6:135–142. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
54
|
Thierry A, Giraud S, Robin A, Barra A,
Bridoux F, Ameteau V, Hauet T, Girard JP, Touchard G, Gombert JM
and Herbelin A: The alarmin concept applied to human renal
transplantation: Evidence for a differential implication of HMGB1
and IL-33. PloS One. 9:e887422014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Gombert JM, Thierry A, Robin A, Barra A,
Thierry H, Touchard G and Herbelin A: Study of alarmin release
during ischemia reperfusion injury after human renal
transplantation (P2214). J Immunol. 190:69.452013.
|
|
56
|
Singbartl K and Kellum JA: AKI in the ICU:
Definition, epidemiology, risk stratification, and outcomes. Kidney
Int. 81:819–825. 2012. View Article : Google Scholar
|
|
57
|
Lee SJ, Borsting E, Declèves AE, Singh P
and Cunard R: Podocytes express IL-6 and lipocalin 2/neutrophil
gelatinase-associated lipocalin in lipopolysaccharide-induced acute
glomerular injury. Nephron Exp Nephrol. 121:e86–96. 2012.
View Article : Google Scholar
|
|
58
|
Akcay A, Nguyen Q, He Z, Turkmen K, Won D,
Hernando AA, Altmann C, Toker A, Pacic A, Ljubanovic DG, et al:
IL-33 exacerbates acute kidney injury. J Am Soc Nephrol.
22:2057–2067. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Ozkok A and Edelstein CL: Pathophysiology
of cisplatin-induced acute kidney injury. Biomed Res Int.
2014:9678262014. View Article : Google Scholar : PubMed/NCBI
|
